Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chester B Whitley

Showing results (61-70 of 116) with videos related to

Pageof 12
Sort By:
Neurobiology of Disease|March 15, 2011
Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type IDaniel A Wolf, Andrew W Lenander, Zhenhong Nan, et al.
The Journal of Pediatrics|May 6, 2004
Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)Paul Harmatz, Chester B Whitley, Lewis Waber, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|April 9, 2013
Low bone mineral content and challenges in interpretation of dual-energy X-ray absorptiometry in children with mucopolysaccharidosis types I, II, and VILynda E Polgreen, William Thomas, Ellen Fung, et al.
Molecular Therapy. Advances|May 15, 2026
CSF GAG non-reducing ends in MPS IH after peripheral and brain-penetrating therapies: A model comparing IV non-targeted ERT and HCTTroy C Lund, John E Wagner, Susie Long, et al.
The Journal of Pediatrics|September 15, 2012
Enzyme replacement is associated with better cognitive outcomes after transplant in Hurler syndromeJulie B Eisengart, Kyle D Rudser, Jakub Tolar, et al.
The Journal of Pediatrics|January 21, 2016
A Prospective Natural History Study of Mucopolysaccharidosis Type IIIAElsa G Shapiro, Igor Nestrasil, Kathleen A Delaney, et al.
Journal of Pediatric Rehabilitation Medicine|December 31, 2014
Isokinetic muscle strength differences in patients with mucopolysaccharidosis I, II, and VINatalie E Taylor, Donald R Dengel, Troy C Lund, et al.
Molecular Genetics and Metabolism|July 12, 2021
A multicenter open-label extension study of intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type AFrits A Wijburg, Chester B Whitley, Joseph Muenzer, et al.
Journal of Inherited Metabolic Disease|February 25, 2023
Persistent bone and joint disease despite current treatments for mucopolysaccharidosis types I, II, and VI: Data from a 10-year prospective studyBradley S Miller, Ellen B Fung, Klane K White, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 15, 2004
Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase geneSeth D Hartung, Joel L Frandsen, Dao Pan, et al.
Pageof 12

Showing results (61-70 of 116) with videos related to

Sort By:
Pageof 12
Neurobiology of Disease|March 15, 2011
Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type IDaniel A Wolf, Andrew W Lenander, Zhenhong Nan, et al.
The Journal of Pediatrics|May 6, 2004
Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)Paul Harmatz, Chester B Whitley, Lewis Waber, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|April 9, 2013
Low bone mineral content and challenges in interpretation of dual-energy X-ray absorptiometry in children with mucopolysaccharidosis types I, II, and VILynda E Polgreen, William Thomas, Ellen Fung, et al.
Molecular Therapy. Advances|May 15, 2026
CSF GAG non-reducing ends in MPS IH after peripheral and brain-penetrating therapies: A model comparing IV non-targeted ERT and HCTTroy C Lund, John E Wagner, Susie Long, et al.
The Journal of Pediatrics|September 15, 2012
Enzyme replacement is associated with better cognitive outcomes after transplant in Hurler syndromeJulie B Eisengart, Kyle D Rudser, Jakub Tolar, et al.
The Journal of Pediatrics|January 21, 2016
A Prospective Natural History Study of Mucopolysaccharidosis Type IIIAElsa G Shapiro, Igor Nestrasil, Kathleen A Delaney, et al.
Journal of Pediatric Rehabilitation Medicine|December 31, 2014
Isokinetic muscle strength differences in patients with mucopolysaccharidosis I, II, and VINatalie E Taylor, Donald R Dengel, Troy C Lund, et al.
Molecular Genetics and Metabolism|July 12, 2021
A multicenter open-label extension study of intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type AFrits A Wijburg, Chester B Whitley, Joseph Muenzer, et al.
Journal of Inherited Metabolic Disease|February 25, 2023
Persistent bone and joint disease despite current treatments for mucopolysaccharidosis types I, II, and VI: Data from a 10-year prospective studyBradley S Miller, Ellen B Fung, Klane K White, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 15, 2004
Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase geneSeth D Hartung, Joel L Frandsen, Dao Pan, et al.
Pageof 12